Key points in Rare primary liver cancers: an EASL position paper
10.3760/cma.j.cn311367-20250226-00079
- VernacularTitle:《罕见原发性肝癌：欧洲肝病学会立场报告》摘译
- Author:
Yalan WANG
1
;
Guohong HAN
1
Author Information
1. 西安国际医学中心医院消化内科，西安 710100
- Publication Type:Journal Article
- Keywords:
Rare primary liver cancer;
Hepatocellular-cholangio-carcinoma;
Fibrolamellar carcinoma;
Hepatocellular adenoma;
Hepatic epithelioid hemangioendothelioma;
H
- From:
Chinese Journal of Digestion
2025;45(7):436-449
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, owing to advances in understanding of hepatocarcinogenesis, the treatment of primary liver cancer (PLC), including hepatocellular-cholangio-carcinoma, fibrolamellar carcinoma, and hepatic epithelioid hemangioendothelioma have garnered increased attention. In this position paper, an international panel of experts representing oncology, hepatology, pathology, radiology, and surgery has systematically summarised the available information and evidence on the pathogenesis, diagnosis, and treatment of rare PLC. While clinical trials of systemic treatments are underway for some rare PLC—more researches, involving national and international collaboration—are required.
